- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Next-generation sequencing, IO Companion diagnostic, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, MSi-H Companion diagnostic, PD(L)-1 companion diagnostic, Pan tumor: Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab. (Pubmed Central) - Sep 15, 2024 Demonstrated analytical and clinical performance of F1CDx led to the pan-tumor FDA approval in 2022 of F1CDx to identify MSI-H solid tumor patients for treatment with pembrolizumab. F1CDx is an accurate, reliable, and FDA-approved method for the identification of MSI-H tumors for treatment with pembrolizumab.
- |||||||||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
Review, Journal, PD(L)-1 Biomarker, IO biomarker: EGFR-mutated NSCLC: A roadmap to treatment sequences. (Pubmed Central) - Sep 15, 2024 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for the management of EGFR-mutated non-small cell lung cancer. Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines. (Pubmed Central) - Sep 15, 2024 Rituximab (RTX) is recommended as a first-line immunosuppressive therapy and shows high clinical efficacy, but the optimal doses remain controversial...Immunoadsorption could be used as an auxiliary choice for severe cases. This article explores new treatments for PMN and highlights possible mechanisms for potential new technologies that offer new ideas for treatment.
- |||||||||| Hansizhuang (serplulimab) / Fosun Pharma
Clinical, P2/3 data, Journal, Metastases: First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial. (Pubmed Central) - Sep 15, 2024 P2/3 The sustained and significant improvement in efficacy with camrelizumab-chemotherapy compared to placebo-chemotherapy, along with the absence of accumulating or delayed toxicities, supports the long-term use of camrelizumab-chemotherapy as a standard therapy in untreated advanced/metastatic ESCC. Serplulimab plus HLX04 and XELOX exhibits promising efficacy and is safe and tolerable in patients with treatment-naive mCRC.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions. (Pubmed Central) - Sep 14, 2024 Biologics, such as rituximab and intravenous immunoglobulin, have shown effectiveness in refractory cases...Additionally, integrated treatment strategies combining pharmacological and non-pharmacological interventions are crucial to improving patient outcomes and quality of life. Understanding the etiology and pathogenesis of DM more deeply will be vital for developing more effective and targeted treatments, ultimately leading to better disease management and prognosis.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, PD(L)-1 Biomarker, IO biomarker: A Transcriptomic Analysis of Laryngeal Dysplasia. (Pubmed Central) - Sep 14, 2024 Following these observed alterations, it is possible to differentiate which dysplasias progress or not or relapse quickly. This information could, in the future, be the basis for determining a close follow-up, minimizing surgical interventions, planning a correct and personalized treatment protocol for each patient and, after specific clinical trials, tailoring new drug treatments.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature. (Pubmed Central) - Sep 14, 2024 Over half received chemotherapy and pembrolizumab as first-line treatment...Combining local approaches with first-line ICI+/- chemotherapy appears to improve survival in brain metastatic NSCLC. A literature review was conducted to explore key questions regarding upfront ICI alone or in combination with systemic drugs or local approaches in brain metastatic NSCLC.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Review, Journal, Metastases: Therapeutical Usefulness of PD-1/PD-L1 Inhibitors in Aggressive or Metastatic Pituitary Tumours. (Pubmed Central) - Sep 14, 2024 Therapeutic options for pituitary neuroendocrine tumours (PitNETs) refractory to temozolomide are scarce...Among 29 patients with PitNETs treated with PD-1/PD-L1 inhibitors, the positive radiological and biochemical response rates were 62.1% and 64.7%, respectively. Altogether, these data suggest a promising role of ICIs in patients with aggressive or metastatic PitNETs refractory to other treatment modalities.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer. (Pubmed Central) - Sep 14, 2024 Median progression-free survival was 5.53 months for HER2-positive patients versus 1.81 months for HER2-negative patients (p = 0.037). Pembrolizumab as a salvage chemotherapy for the treatment of AGC demonstrated superior effectiveness in HER2-positive patients compared with HER2-negative patients.
- |||||||||| Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
Retrospective data, Review, Journal: Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Na (Pubmed Central) - Sep 14, 2024 High-grade (?3) adverse events (AEs) that were more common with 4-drug regimens were infections (RR: 1.34; 95% CI 1.17; 1.54) and thrombocytopenia (RR: 1.39; 95% CI 1.12; 1.74). This study suggests that 4-drug induction regimens which include an anti-CD38 antibody improve efficacy although with additional toxicity in NDMM patients.
- |||||||||| Bavencio (avelumab) / EMD Serono, Stivarga (regorafenib) / Bayer
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1?+?antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics. (Pubmed Central) - Sep 14, 2024 Additionally, peripheral biomarker assessments identified elevated levels of cytokines, including CSF-1, IL-4, IL-8, and TWEAK, correlating with adverse clinical outcomes, thereby accentuating the role of macrophage infiltration in mediating resistance. These insights furnish an invaluable foundation for elucidating, and potentially circumventing, resistance mechanisms in current AGC therapeutic paradigms, emphasizing the integral role of tumor microenvironmental dynamics and immune modulation.
- |||||||||| Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Endostar (recombinant human endostatin) / Simcere
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: ?-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer. (Pubmed Central) - Sep 14, 2024 These insights furnish an invaluable foundation for elucidating, and potentially circumventing, resistance mechanisms in current AGC therapeutic paradigms, emphasizing the integral role of tumor microenvironmental dynamics and immune modulation. ?-glucan combined with Envafolimab and Endostar has considerable efficacy and safety for immune rechallenge in metastatic NSCLC patients who failed of anti-PD-1 treatment previously, especially for PD-L1 positive patients.
- |||||||||| Journal, Adverse events: Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. (Pubmed Central) - Sep 14, 2024
Signals for peripheral sensory neuropathy were 4.83, 2.44, 2.74, and 2.21 (calculated based on IC025) for brentuximab vedotin, trastuzumab emtansine, enfortumab vedotin, and polatuzumab vedotin, while signals for peripheral motor neuropathy were 5.31, 0.34, 2.27, and 0.03, respectively...Tisotumab vedotin had the highest hospitalization rate at 26.67%, followed by brentuximab vedotin at 25.5%...Brentuximab vedotin and enfortumab vedotin showed similar profiles for peripheral sensory neuropathy and motor neuropathy. Given the delayed time to onset and potentially poor outcomes, ADC-related peripheral neuropathy warrants significant attention.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay. (Pubmed Central) - Sep 14, 2024 By computational evaluation of response profiles followed by subsequent m/z feature annotation via fragmentation analysis and trapped ion mobility MS, we identified adenosine triphosphate and glutathione as readily MS-assessable metabolite markers for CDC and demonstrate that robust concentration-response characteristics can be obtained by MALDI-TOF MS. Statistical assay performance indicators suggest that whole-cell MALDI-TOF MS could complement the toolbox for functional cellular testing of biopharmaceuticals.
|